Company Description
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders.
It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors.
The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea.
It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications.
It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders.
The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015.
RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.
| Country | United States |
| Founded | 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Dr. Arnold S. Lippa Ph.D. |
Contact Details
Address: 126 Valley Road, Suite C Glen Rock, New Jersey 07452 United States | |
| Phone | (201) 444-4947 |
| Website | respirerx.com |
Stock Details
| Ticker Symbol | RSPI |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000849636 |
| CUSIP Number | 761227305 |
| ISIN Number | US7612273059 |
| Employer ID | 33-0303583 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Arnold S. Lippa Ph.D. | Executive Chairman, Interim President, Interim Chief Executive Officer and Chief Scientific Officer |
| Dr. Jeff Eliot Margolis | Senior Vice President, Chief Financial Officer, Treasurer, Secretary and Director |
| Richard D. Purcell | Senior Vice President of Research and Development |
| David Dickason | Senior Vice President of Pre-Clinical Product Development |
| Marc M. Radin | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 2, 2024 | 8-K | Current Report |
| Jan 22, 2024 | 8-K | Current Report |
| Dec 11, 2023 | 8-K | Current Report |
| Nov 17, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Oct 12, 2023 | 8-K | Current Report |
| Oct 2, 2023 | 8-K | Current Report |
| Aug 21, 2023 | 10-Q | Quarterly Report |